---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-025064"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:12:32.529620+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025

## Summary
- Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.
- R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.
- Cash $17.8M; expects funding operations into second half 2025.
- Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.
- Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites.

## SEC filing metadata
- accession: 0001140361-24-025064
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/0001140361-24-025064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/ef20028745_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-025064
- JSON: https://secwatch.observer/filing/0001140361-24-025064.json
- Plain text: https://secwatch.observer/filing/0001140361-24-025064.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported first quarter ended March 31, 2024 results: revenue $271,140, net income $3,599,510, EPS $0.17.
  - Period: first quarter ended March 31, 2024
  - Revenue: $271,140
  - Net income: $3,599,510
  - EPS: $0.17
  - Result: reported results
  source text: Quarter Ended March 31, 2024 • Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023 • Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023 • Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/0001140361-24-025064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.